GlassScriptPhysician profile
Pamela Mclain
NPI 1083661961
$555,845.77
in general payments reported to CMS, 2019-2025
12 companies · $217K in 2025
The $217K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $16.54 · 2021: $801 · 2022: $79K · 2023: $76K · 2024: $181K · 2025: $217K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $475K · Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $474,802.50 |
| Food and Beverage | $526.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553,769.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $736.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $319.78 | 2021-2023 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $243.69 | 2019 | |
| Mallinckrodt Hospital Products INC. | $149.99 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Radius Health, INC. | $121.18 | 2019-2020 | |
| Amgen INC. | $107.55 | 2019 | |
| Janssen Biotech, INC. | $71.66 | 2023 | Tremfya |
| Aurinia Pharma U.S., INC. | $60.84 | 2021 | |
| Fresenius Kabi USA, LLC | $15.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.